Skip to main content

Advertisement

Log in

Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer

  • Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)
  • Published:
Current Colorectal Cancer Reports

Abstract

The treatment of patients with colorectal cancer with colorectal liver metastases remains an exciting challenge for the multidisciplinary team. The role and choice of induction chemotherapy, the timing of surgery in resectable disease and the prioritisation of resection of the primary or the metastases are all still controversial. A true multidisciplinary approach and individualisation of treatment strategies are recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Leporrier J, Maurel J, Chiche L, et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465–74.

    Article  CAS  PubMed  Google Scholar 

  2. Huiskens J, van Gulik TM, van Lienden KP, et al. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 2015;15:365.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Shah SA, Bromberg R, Coates A, Rempel E, Simunovic M, Gallinger S. Survival after liver resection for metastatic colorectal carcinoma in a large population. J Am Coll Surg. 2007;205:676–83.

    Article  PubMed  Google Scholar 

  5. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254–62.

    Article  CAS  PubMed  Google Scholar 

  6. Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg. 2008;15:570–80.

    Article  PubMed  Google Scholar 

  7. Lygidakis N, Ziras N, Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy—immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology. 1995;42:155–61.

    CAS  PubMed  Google Scholar 

  8. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol. 2002;20:1499–505.

    Article  PubMed  Google Scholar 

  9. Parks R, Gonen M, Kemeny N, Jarnagin W, D’Angelica M, DeMatteo R, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753–61.

    Article  PubMed  Google Scholar 

  10. Laurent C, Adam JP, Denost Q, Smith D, Saric J, Chiche L. Significance of R1 resection for advanced colorectal liver metastases in the era of modern effective chemotherapy. World J Surg. 2016;40(5):1191–9. This retrospective study of 466 patients treated between 1999 and 2010 in a major centre of expertise suggests that with modern combination chemotherapy, R1 resection is less crucial in responders to neoadjuvant chemotherapy. Additional postoperative chemotherapy may also protect from recurrences whatever the margin resection status.

    Article  PubMed  Google Scholar 

  11. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.

    Article  PubMed  Google Scholar 

  15. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Nordlinger B, Sorbye H, Glimelius B, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Primrose J, Falk S, Finch-Jones M, Valle J, Sherlock D, Hornbuckle J, et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: the new EPOC study. Lancet Oncol. 2014;15(6):601–11. This randomised phase III trial has caused huge controversy (see J Clin Oncol correspondence Nordlinger et al 2015).The study suggests that the addition of cetuximab to chemotherapy in resectable (but multiple) CRLM is associated with a worse outcome. Criticisms have focussed on the changing eligibility criteria, multiple options for chemotherapy and poor quality of the surgery.

    Article  CAS  PubMed  Google Scholar 

  18. National Clinical Practice Guidelines in Oncology (NCCN Guidelines): Rectal Cancer Version 2.2016 www.ncrn.org. (last accessed 15/06/2016)

  19. NICE. Colorectal cancer: The diagnosis and management of colorectal cancer. Available from: https://www.nice.org.uk/guidance/cg131/resources/guidance-colorectal-cancer-pdf.

  20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.

    Article  PubMed  Google Scholar 

  21. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–9.

    Article  CAS  PubMed  Google Scholar 

  22. Folprecht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018–25.

    Article  CAS  PubMed  Google Scholar 

  23. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.

    Article  PubMed  Google Scholar 

  24. Jang KU, Kim CW, Kim KH, Lim SB, Yu CS, Kim TW, et al. Prognostic factors in terms of the number of metastatic nodules in patients with colorectal cancer liver metastases. Ann Coloproctol. 2016;32:92–100.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Margonis GA, Sasaki K, Kim Y, Samaha M, Buettner S, Amini N, et al. Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases. J Gastrointest Surg. 2016;6 [Epub ahead of print].

  26. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.

    PubMed  Google Scholar 

  27. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.

    Article  CAS  PubMed  Google Scholar 

  28. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.

    Article  CAS  PubMed  Google Scholar 

  29. Van Cutsem E, Kohne C, Lang I, Folprecht G, Nowacki M, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.

    Article  PubMed  CAS  Google Scholar 

  30. Okines A, Puerto O, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer. 2009;101:1033–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110(12):2761–7.

    Article  PubMed  Google Scholar 

  32. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26(11):1830–5.

    Article  CAS  PubMed  Google Scholar 

  33. Bertolini F, Malavasi N, Scarabelli L, et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer. 2011;104(7):1079–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22(9):2042–8.

    Article  CAS  PubMed  Google Scholar 

  35. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology. Br J Cancer. 2006;94:798–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.

    Article  CAS  PubMed  Google Scholar 

  37. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21–30.

    Article  PubMed  Google Scholar 

  38. Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20(13):4289–97. In this phase II study in patients with initially unresectable or not optimally resectable CRLM, FOLFOXIRI showed a conversion rate to resectability of 67 %, and was much more effective than the standard conventional chemotherapy (FOLFIRI/FOLFOX4).On this basis the randomised phase II METHEP-2 confirmed triplet chemotherapy, in association with a targeted therapy, showed a higher rate of R0/R1 resections than standard (FOLFIRI or FOLFOX4) combined with the same targeted therapy, but with a statistically significant difference in terms of OS.

    Article  PubMed  Google Scholar 

  39. Bendell JC, Zakari A, Peyton JD, et al. A phase II study of FOLFOXIRI plus panitumumab followed by evaluation for resection in patients with metastatic KRAS wild-type colorectal cancer with liver metastases only. Oncologist. 2016;21(3):279–80. doi:10.1634/theoncologist.2015-0439.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15.

    Article  CAS  PubMed  Google Scholar 

  41. Hecht J, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.

    Article  CAS  PubMed  Google Scholar 

  42. Tol J, Koopman M, Cats A, Rodenburg C, Creemers G, Schrama J, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.

    Article  CAS  PubMed  Google Scholar 

  43. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll H, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  44. Fakih M. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33:1809–24.

    Article  CAS  PubMed  Google Scholar 

  45. Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3). doi:10.1093/jnci/dju427.

  46. Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34(9):384–93.

    CAS  PubMed  Google Scholar 

  47. Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32:5s (suppl; abstract LBA3).

    Google Scholar 

  48. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.

    Article  CAS  PubMed  Google Scholar 

  49. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32:2240–7.

    Article  CAS  PubMed  Google Scholar 

  50. Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil BH, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34:suppl; abstract 3504.

    Google Scholar 

  51. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–8.

    PubMed  Google Scholar 

  53. Spelt L, Andersson B, Nilsson J, Andersson R. Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review. Eur J Surg Oncol. 2012;38:16–24.

    Article  CAS  PubMed  Google Scholar 

  54. Nigri G, Petrucciani N, Ferla F, et al. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies. Surg – J R Coll Surg Edinb Irel. 2015;13:83–90.

    Google Scholar 

  55. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052–61.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Reddy SK, Barbas AS, Turley RS, et al. A standard definition of major hepatectomy: resection of four or more liver segments. HPB (Oxford). 2011;13:494–502.

    Article  Google Scholar 

  58. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.

    Article  CAS  PubMed  Google Scholar 

  59. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94:274–86.

    Article  CAS  PubMed  Google Scholar 

  60. Grat M, Hoówko W, Lewandowski Z, et al. Early post-operative prediction of morbidity and mortality after a major liver resection for colorectal metastases. HPB (Oxford). 2013;15:352–8.

    Article  Google Scholar 

  61. Choti MA, Thomas M, Wong SL, et al. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann Surg Oncol. 2016;23(2):375–81.

    Article  PubMed  Google Scholar 

  62. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.

    Article  CAS  PubMed  Google Scholar 

  63. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

    Article  PubMed  CAS  Google Scholar 

  64. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.

    Article  CAS  PubMed  Google Scholar 

  65. Adams RA, Meade AM, Seymour MT, MRC COIN Trial Investigators, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12:642–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015;16:1355–69.

    Article  CAS  PubMed  Google Scholar 

  67. Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385:1843–52.

    Article  CAS  PubMed  Google Scholar 

  68. Finlay IG, Meek D, Brunton F, McCardle CS. Growth rate of hepatic metastases in colorectal cancer. Br J Surg. 1989;76:652.

    Article  CAS  PubMed  Google Scholar 

  69. Kito A, Tanaka K, Fujimaki H, Nakazawa M, Togo S, Minami M. Tumor doubling time and local immune response to hepatic metastases from colorectal cancer. J Surg Oncol. 2007;96:525–33.

    Article  PubMed  Google Scholar 

  70. Lim E, Wiggans MG, Shahtahmassebi G, et al. Rebound growth of hepatic colorectal metastases after neo-adjuvant chemotherapy: effect on survival after resection. HPB (Oxford). 2016;18(7):586–92.

    Article  Google Scholar 

  71. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion 318-21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252(5):774–87.

    Article  PubMed  Google Scholar 

  73. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80.

    Article  PubMed  Google Scholar 

  74. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg. 2012;255(2):237–47.

    Article  PubMed  Google Scholar 

  75. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–18.

    Article  PubMed  CAS  Google Scholar 

  76. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–82.

    Article  CAS  PubMed  Google Scholar 

  77. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20(12):1964–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel Krell.

Ethics declarations

Conflict of Interest

Daniel Krell has served on an advisory board for Servier.

Rob Glynne-Jones has received speaker’s honoraria from Merck and Servier; has served on advisory boards for Eli Lilly & Co., Roche, Home Nutrition, Servier, Eisai and Amgen; and has participated in ESMO’s preceptorship program.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Adjuvant Therapy for Colon Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krell, D., Glynne-Jones, R. Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 12, 303–313 (2016). https://doi.org/10.1007/s11888-016-0342-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-016-0342-5

Keywords

Navigation